Olokizumab
- Generic Name
- Olokizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1007223-17-7
- Unique Ingredient Identifier
- PAI71R1D2W
- Background
Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman dise...
- Associated Conditions
- -
- Associated Therapies
- -
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 3087
- Registration Number
- NCT05196477
- Locations
- 🇷🇺
State Budgetary Healthcare Institution "Regional Hospital â„– 3", Chelyabinsk, Russian Federation
🇷🇺State Budgetary Institution of Healthcare of Tver region "Regional clinical hospital", Tver, Russian Federation
🇷🇺Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" under the Ministry of Health of the Russian Federation, Kazan, Tatarstan, Russian Federation
Study of Efficacy of Different Treatment Regimens of Olokizumab
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 198
- Registration Number
- NCT05187793
- Locations
- 🇷🇺
State Budgetary Healthcare Institution "City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department", Moscow, Russian Federation
🇷🇺Federal State Budgetary Institution "Central Clinical Hospital with a Polyclinic" of Presidential Administration of the Russian Federation, Moscow, Russian Federation
🇷🇺State Budgetary Healthcare Institution "City Clinical Hospital № 52 of Moscow Healthcare Department", Moscow, Russian Federation
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT04246762
- Locations
- 🇧🇬
Comac Medical Ltd, Sofia, Bulgaria
🇲🇩ICS ARENSIA Exploratory Medicine SRL, a daughter company of ARENSIA Exploratory Medicine GmbH,Republican Clinical Hospital, Chisinau, Moldova, Republic of
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 368
- Registration Number
- NCT02760433
- Locations
- 🇧🇷
CEDOES - Diagnóstico e Pesquisa, Vitória, EspÃrito Santo, Brazil
🇧🇷CMiP - Centro Mineiro de Pesquisa, Juiz de Fora, Minas Gerais, Brazil
🇧🇷Hospital Bruno Born, Lajeado, Rio Grande Do Sul, Brazil
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 428
- Registration Number
- NCT02760368
- Locations
- 🇷🇺
SBEI HPE "Rostov State Medical University" of Ministry of Health of the Russian Federation, Rostov, Rostovskaya Oblast, Russian Federation
🇷🇺SBHI of the Republic of Karelia "Republican Hospital named after V.A. Baranov", Petrozavodsk, Republic Of Karelia, Russian Federation
🇷🇺SBHI of Stavropol Region "Stavropol Regional Clinical Hospital", Stavropol', Stavropol Region, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.